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Abstract
Background: Depression is a common comorbid psychiatric symptom in patients with Alzheimer’s disease (AD),
and the prevalence of depression is higher among people with AD compared with healthy older adults. Comorbid
depression in AD may increase the risk of cognitive decline, impair patients’ function, and reduce their quality of
life. However, the mechanisms of depression in AD remain unclear. Here, our aim was to identify neurometabolic
characteristics in the brain that are associated with depression in patients with mild AD.
Methods: Thirty-seven patients were evaluated using the Neuropsychiatric Inventory (NPI) and Hamilton Depression
Rating Scale (HAMD-17), and divided into two groups: 17 AD patients with depression (D-AD) and 20 non-depressed
AD patients (nD-AD). Using proton magnetic resonance spectroscopy, we characterized neurometabolites in
the anterior cingulate gyrus (ACG) of D-AD and nD-AD patients.
Results: Compared with nD-AD patients, D-AD patients showed lower N-acetylaspartate/creatine (NAA/Cr) and
higher myo-inositol/creatine (mI/Cr) in the left ACG. NPI score correlated with NAA/Cr and mI/Cr in the left
ACG, while HAMD correlated with NAA/Cr.
Conclusions: Our findings show neurometabolic alterations in D-AD patients. Thus, D-AD pathogenesis may
be attributed to abnormal activity of neurons and glial cells in the left ACG.
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Background
Depression is a common comorbid psychiatric symptom
in patients with Alzheimer’s disease (AD). It is associated
with cognitive decline in AD patients, and reduced qual-
ity of life in patients and their caregivers [1]. Currently,
there are no effective therapeutic interventions. There-
fore, discovering and understanding the mechanisms
and biological signatures related to depression in AD
has clinical value.
Neuroimaging studies have yielded mixed results on re-
gional brain volume differences between depressed and
non-depressed AD patients. Son et al. [2] reported that
AD patients with depression show decreased gray matter
volume in the left inferior temporal gyrus compared with
non-depressed AD patients. Moreover, Lebedev et al. [3]
reported cortical thinning in left parietal and temporal
brain regions in AD patients with depressive symptoms
compared with non-depressed AD patients. They also
reported strong negative correlation between cortical
thickness in the precuneus and parahippocampal cortex
and total tau (t-τ) (an AD biomarker) in the cerebrospinal
fluid of depressed compared with non-depressed AD
patients. Hu et al. [4] reported significant correlation
between depression assessed with the Neuropsychiatric
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Inventory (NPI) and gray matter atrophy in the left middle
frontal cortex. However, this was not supported by Bruen
et al. [5]. Studies using single photon emission computed
tomography show reduced perfusion in the middle frontal
gyrus [6] and dorsolateral prefrontal (DLPFC) [7] regions
in AD patients with depression.
These conflicting findings may partly be owing to limi-
tations of the image analysis methods. For example, meta-
bolic data from positron emission tomography (PET)
studies are usually expressed relative to the whole brain or
a specific structure. Therefore, as it does not reflect an
absolute metabolic rate, PET may only indirectly reflect
regional neuronal activity. In addition, structural measures
are not sensitive to neuronal function at early stages [8].
Histological studies of postmortem samples from well-
characterized depressed individuals who have committed
suicide show altered cortical dendritic branching of pyr-
amidal neurons in the ACC [9]. Additionally, the ratio of
primed over ramified microglia in the dorsal ACC is
significantly increased in depressed individuals who have
committed suicide compared with healthy controls [10].
Hence, investigation of neurons and glial cells may aid our
understanding of depression pathogenesis in AD patients.
Proton magnetic resonance spectroscopy (1H-MRS) is a
noninvasive magnetic resonance imaging (MRI) method
to measure brain metabolite concentrations, including the
neuronal marker N-acetylaspartate (NAA), the membrane
phospholipid product choline (Cho), the second messen-
ger metabolite and gliosis marker myo-inositol (mI), and
total creatine (Cr), which includes creatine and phospho-
creatine and is used as an internal standard [11]. 1H-MRS
has been used in clinical studies of major depressive
disorder (MDD) [12, 13] and AD [11]. Studies in patients
with MDD compared with healthy controls report de-
creased NAA [14], decreased mI [15], and normal Cho/Cr
[16] in the anterior cingulate cortex (ACC). Furthermore,
treatment of MDD with lamotrigine and antidepressants
may increase NAA and mI in the ACC [14, 15]. 1H-MRS
findings also suggest that AD patients exhibit reduced
NAA/Cr and elevated mI/Cr ratios in the medial temporal
lobe, posterior cingulate gyrus, temporoparietal lobe,
hippocampus, and prefrontal lobe [11].
Recently, several studies have been performed using
1H-MRS in AD patients with behavioral and psycho-
logical symptoms. One study of 30 AD patients found
significantly lower NAA/Cr and higher mI/Cr ratios in
patients with delusions compared to those without. Add-
itionally, patients with activity disturbances had signifi-
cantly lower NAA/Cr in the ACC compared to those
without, but there was no relationship between depres-
sion and NAA/Cr or mI/Cr [17]. Another study of
36 AD patients, 19 patients with amnestic mild cognitive
impairment (aMCI), and 23 cognitively normal (CN)
subjects revealed statistically significant correlations
between mI/Cr in ACG and total NPI scores. However,
the relationship between the depressive domain of NPI
and brain metabolites was not specifically investigated
[18]. Tsai et al. [19] reported a positive correlation be-
tween depression in AD and the Cho/Cr ratio in the left
DLPFC, and mI/Cr ratio in both the left and right cingu-
late gyrus. In contrast, in a trial of donepezil versus
memantine treatment for AD, no significant correlations
between 1H-MRS in the ACG and depression were re-
ported [20]. Therefore, the underlying pathophysiology
of AD with depression remains unclear. Inconsistencies
may result from heterogeneity in previous research sub-
jects, for example, AD patients may have more than one
component of behavioral and psychological symptoms.
Furthermore, few studies of depression in AD patients
using 1H-MRS have been performed to date.
The main purpose of our study was to investigate the re-
lationship between depression and brain metabolites in
AD patients. Given the known involvement of the ACG in
MDD and AD, we examined its contribution to depression
in AD patients, and hypothesized that metabolic changes
would be observed in depressed AD patients. Thus, we in-
vestigated ACG metabolites using 1H-MRS in AD patients
with and without depression.
Methods
Patients
Thirty-seven patients with mild AD were recruited be-
tween December 2013 and December 2014 from Zhejiang
Mental Health Center, China. All patients met the criteria
for probable AD from the National Institute of Neuro-
logical and Communicative Diseases and Stroke and
Alzheimer’s Disease and Related Disorders Association
[21]. Patients’ scores ranged from 18 to 24 on the Mini-
Mental State Examination (MMSE) and all patients had
a score of 1 on the Clinical Dementia Rating (CDR)
scale. A diagnosis of depression was confirmed using
the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV) [22]. Depression severity
was assessed using the Hamilton Depression Rating
Scale (HAMD-17) and NPI [23]. AD patients with
depression (D-AD) had a score of 1 on the depression
domain and a score of 0 on any of the other 11 NPI
domains, and scored ≥ 7 on HAMD-17. Based on rec-
ommendations for inclusion criteria for clinical trials,
D-NPI scores of ≥ 4 are indicative of clinical signifi-
cance [24]. Non-depressed AD patients (nD-AD) did
not meet DSM-IV criteria for depression. All scales
were administered by trained neuropsychologists. All
patients were right-handed, had more than 6 years’
education, and were aged between 65 and 80 years.
Caregivers were a patient’s spouse and/or first-degree
relative, and also had more than 6 years’ education.
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Patients with a history of neurological disorders (e.g.,
active epilepsy), psychiatric illnesses (e.g., schizophrenia,
major depression, or mania), traumatic brain injury, those
taking psychotropic medications, and significant alcohol
and/or other substance abuse issues were excluded. To
minimize the risk of concomitant vascular pathology, sub-
jects were also excluded if dual-echo MR images showed
two or more hyperintense lesions with diameters ≥ 5 mm,
or more than four hyperintense lesions with diameters
between 0 and 5 mm.
All participants (or their legal representatives) provided
formal written consent. The research protocol was ap-
proved by the Ethics Committee of Tongde Hospital
of Zhejiang Province (No.2013-001).
MRI and MR spectroscopy
MRI and 1H-MRS were acquired for all study partici-
pants on a 3.0 Tesla unit (Siemens MAGNETOM Verio;
Siemens Medical Systems, Erlangen, Germany) using an
eight-channel phased-array head coil. Foam padding and
headphones were used to reduce head motion and scan-
ner noise. Advanced shimming, as provided by the manu-
facturer, was performed automatically to optimize field
homogeneity. A two-dimensional chemical shift imaging
sequence (CSI), using a point-resolved spectroscopy
(PRESS) technique, was used to acquire water-suppressed
1H-MRS simultaneously from the left and right cingu-
late region. The imaging parameters were: echo time
(TE) = 35 ms, repetition time (TR) = 1500 ms, and
average = 4, including ‘weighted’ mode used for k-space ac-
quisition, with matrix size = 16 × 16 without interpolation,
field-of view (FOV) = 160 mm, voxel of interest (VOI) =
80 mm, slice thickness = 1.5 cm, and ‘fully excited VOI’
was switched on. T2-weighted transverse, sagittal, and cor-
onal gradient echo images (TR/TE = 600/95 ms) were
acquired to localize the 1H-MRS signal. A line was drawn
perpendicular to the AC-PC line, which also cut across the
medial section of the genu of the corpus callosum. The
VOI in the anterior cingulate was located in front of the
line. The VOI mainly consisted of the dorsal ACC and part
of the lateral prefrontal cortex (PFC) [25, 26] (Figure 1).
Total acquisition time for both MRI and MRS was ap-
proximately 10 min. Spectra data were post-processed
using a commercially available, spectral analysis software
package (Syngo spectroscopy post-processing package,
Siemens Healthcare, Erlangen, Germany). The spectrum
covered a frequency range of 4.3–0.1 ppm. Peak areas of
NAA, mI, and Cr were estimated, and ratios of the area
under each peak were expressed relative to Cr in each
spectrum (Figure 2). Voxel placement for spectroscopy
and all data analysis were performed by one experienced
radiologist who was blind to each subjects’ diagnosis,
and confirmed by another radiologist and one physician.
VOI position was carefully adjusted to minimize white
matter and cerebrospinal fluid contamination.
Data analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences, Version 15.0 (SPSS, Inc.,
Chicago, IL, USA). Demographic and clinical character-
istics of D-AD and nD-AD patients were assessed using
independent-samples t-tests and χ2 tests. Differences be-
tween metabolite ratios relative to Cr (NAA/Cr, Cho/Cr,
and mI/Cr) in the left and right ACG were tested using
independent-samples t-tests. Pearson’s correlation ana-
lysis was used to investigate the correlation between
metabolite ratios and NPI and HAMD scores. Statistical
significance was set at P < 0.05.
Results
Table 1 lists the demographic and clinical data for both
groups. Thirty-seven mild AD patients were included in
the study. Seventeen AD patients had depressive symp-
toms. Scores on the depression domain of NPI (D-NPI)
Fig. 1 Axial T2-weighted localizing images for placement of the MRS region-of-interest. The voxel for MRS examination was located in the
left anterior cingulate gyrus (ACG) (rectangle 1) at the mid-sagittal level (a), and right ACG (square 1) and left ACG (square 2) in the coronal section (b).
Voxel size = 10 mm× 10 mm× 15 mm.
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ranged between 4 and 9, with a mean of 6.76 ± 2.1.
There were no significant differences in sex, age, educa-
tion or MMSE between the D-AD and nD-AD groups
(P > 0.05).
Table 2 shows the ratio of measurements obtained by
1H-MRS. There were significant differences in the ratios
of NAA/Cr and mI/Cr in the left ACG. In addition, the D-
AD group had a lower NAA/Cr ratio than the nD-AD
group (1.35 ± 0.18 vs. 1.50 ± 0.23, respectively; t = −2.161,
P < 0.05). Similarly, the D-AD group had a higher mI/Cr
ratio than the nD-AD group (0.66 ± 0.13 vs. 0.58 ± 0.09,
respectively; t = 2.213, P < 0.05). No differences were found
in ratios between groups in the right ACG (P > 0.05).
Pearson’s correlation analysis of the D-AD group de-
tected statistically significant correlations between NPI
scores and NAA/Cr and mI/Cr ratios of the left ACG
(r = −0.717, P = 0.001; r = 0.492, P = 0.045). Similarly,
statistically significant correlation between HAMD and
NAA/Cr ratio of the left ACG was detected (r = −0.778,
P = 0.000).
Discussion
To the best of our knowledge, this is the first study to
examine neurometabolic characteristics by 1H-MRS in
the ACG of AD patients with depression. The major
findings of our study are: (1) Compared with nD-AD pa-
tients, D-AD patients show lower NAA/Cr and higher
mI/Cr ratios in the left ACG; and (2) correlation be-
tween NPI and HAMD scores and NAA/Cr and mI/Cr
ratios of the left ACG suggest abnormalities in ACG
neurometabolites are associated with depression in AD.
The ACG processes the integration of cognition and
affect [27, 28]. It is also implicated in MDD, in which ab-
normal metabolism [29, 30], decreased blood flow [31], re-
duced gray matter volume [32–34], and ACG involvement
in disrupted brain networks [35] have been observed. In a
post-mortem examination of depressed individuals that
committed suicide, alterations in dendritic branching and
microglial phenotypes were observed in the ACC [9]. A
Fig. 2 Examples of 1H-MRS spectra acquired from one voxel in D-AD and AD groups. Note the lower NAA/Cr and higher mI/Cr ratios in D-AD
subjects (a) compared with nD-AD (b) (CSI, PRESS, voxel size = 10 mm× 10 mm× 15 mm).
Table 1 Demographics and neuropsychological data
D-AD nD-AD t/χ2 p
Gender, n (M/F) 17(8/9) 20(9/11) 0.016 0.900
Age, years 72.9 ± 5.5 74.7 ± 6.3 −0.892 0.379
Education, years 8.6 ± 1.84 8.5 ± 1.83 0.213 0.853
MMSE 21.6 ± 2.8 22.1 ± 2.4 −0.603 0.551
D-NPI 6.76 ± 2.1 0 - -
HAMD 12.3 ± 3.85 3.8 ± 1.57 14.150 0.000
Data represent mean ± SD. Data were analyzed using independent-samples
t-tests and χ2 tests
AD alzheimer’s disease, D-AD alzheimer’s disease with depression, nD-AD
non-depressed AD patients, M male, F female, MMSE mini-mental state
examination, D-NPI depression domain of neuropsychiatric inventory,
HAMD hamilton depression rating scale
Table 2 1H-MRS in the left and right ACG between D-AD and
nD-AD groups
D-AD nD-AD t p
NAA/Cr 1.35 ± 0.18 1.50 ± 0.23 −2.161 0.038
Left ACG Cho/Cr 0.94 ± 0.25 0.89 ± 0.14 0.846 0.403
mI /Cr 0.66 ± 0.13 0.58 ± 0.09 2.213 0.033
NAA/Cr 1.47 ± 0.28 1.52 ± 0.40 −0.463 0.646
Right ACG Cho/Cr 0.89 ± 0.18 0.87 ± 0.12 0.463 0.646
mI /Cr 0.61 ± 0.13 0.59 ± 0.09 0.305 0.762
Data represent mean ± SD
ACG anterior cingulate gyrus, AD alzheimer’s disease, D-AD alzheimer’s disease
with depression, nD-AD non-depressed AD patients
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recent neuroimaging study of depression in AD found
that depression is associated with damage to structures
in specific neural networks and functional disruption of
cortical neural systems involving the ACG [8]. There-
fore, the ACG is considered a crucial region in the
neuronal circuitry underlying depression pathophysi-
ology. Our observation that D-AD patients have abnor-
malities in ACG neurometabolites is consistent with
this. Accordingly, it is likely that the ACG also under-
lies depressive symptoms in AD patients.
NAA is the most prominent 1H-MRS peak, and only
found in the nervous system. It is a marker of neuronal
density or function, osmoregulation, and energy homeo-
stasis. There is a direct relationship between NAA syn-
thesis, oxygen consumption, and ATP production in the
central nervous system [36, 37]. Reduction in NAA
levels measured by 1H-MRS are a recognized marker of
neuronal loss or dysfunction in depressive disorders
[38]. Previous studies have demonstrated that MDD and
bipolar disorder patients have lower NAA/Cr levels than
healthy controls in the PFC, medial frontal cortex, and
ACG [14, 15, 39, 40]. Longitudinal research also shows
that NAA/Cr in the pregenual ACC of patients with
MDD significantly decreases over 9–10 months, and at
baseline, has a logarithmic negative association with illness
duration [41]. Furthermore, successful treatment of MDD
with antidepressants is associated with normalization of
NAA levels in the ACC [14, 15]. More specifically, a grow-
ing body of research suggests that MDD patients exhibit
decreased beta nucleoside triphosphates compared with
healthy controls [42, 43]. These studies, along with our
finding of lower NAA/Cr in D-AD patients, implicates
neuronal degeneration and dysfunction in the ACG of
depressed AD patients.
mI is considered a maker of glial proliferation [44]. It
is also involved in the regulation of neuronal osmolarity,
metabolism of membrane-bound phospholipids, and the
phosphoinositide secondary messenger pathway. Several
animal studies of depression report higher mI/Cr in
the PFC of depressed compared with control animals
[45, 46]. Lirng et al. [47] observed that migraine patients
with MDD had higher mI/Cr ratios in the bilateral DLPFC
compared with patients without MDD. Furthermore, mI/
Cr in the right DLPFC positively correlates with scores
on the Beck Depression Inventory, suggesting that in-
creased mI/Cr within the DLPFC might be associated
with MDD in migraine patients. Torres-Platas et al.
[48] reported hypertrophic astrocytes in the ACG of 10
well-characterized depressed suicide cases. Recently, they
reported increased microglial priming and increased gene
expression of microglial markers in the dorsal ACG in
postmortem brain samples from middle-aged depressed
individuals who committed suicide [10]. Higher mI/Cr in
the ACG of D-AD patients observed in our study is
consistent with these previous studies. We suggest that
higher mI/Cr in the ACG region reflects increased glial
content and activation. Therefore, our study provides fur-
ther evidence for the involvement of ACG glial cells in
depression of AD patients.
We also found that D-AD patients have abnormal
neurometabolic changes in the left ACG, but not the
right ACG, suggesting asymmetrical alterations across
hemispheres. Prior studies have also shown evidence of
asymmetrical ACG abnormalities in late-life depressed
(LLD) patients. Disabato et al. [49] found significantly
smaller left anterior cingulate thickness in late-onset LLD
compared with early-onset LLD subjects. The late-onset
group also had more hyperintensities than early-onset
LLD subjects. Similarly, Yuan et al. [50] found abnormal
left ACG volume in geriatric depression (RGD) patients
compared with healthy control subjects. Furthermore,
there was a significant correlation between left ACG vol-
ume and Rey Auditory Verbal Learning Test delayed recall
raw score in RGD patients. Ritchie et al. [51] confirmed
that early-onset depression and late-onset depression ex-
hibit heterogeneity in etiology, including onset age. These
findings indicate that age at onset of depressive symptoms
in LLD subjects is associated with differences in cortical
thickness. Moreover, the left ACG might be involved in
psychopathology and pathophysiology of RGD. One study
using 11C-Pittsburgh Compound B PET imaging found
more amyloid plaques in the ACG of LLD patients com-
pared with controls [52]. Meanwhile, another longitudinal
study of brain metabolic changes during the conversion
from aMCI to AD, found that converters had a signifi-
cantly greater metabolic decrease in the left ACG than
non-converters [53]. Therefore, we speculate that the left
ACG might be involved in the psychopathology of depres-
sion in AD patients.
Some potential limitations of our study should be
taken into consideration. First, we used a semi-
quantitative MRS approach, in which the intensity of
each metabolite is normalized to Cr under the as-
sumption that Cr concentration remains relatively
constant in different brain diseases. This method is
the most frequently used method for clinical MRS
studies [54]. However, variations in Cr concentration
are present during tissue destruction or in systemic
diseases. Subsequent studies with absolute measures
may revalidate our findings. Second, only the ACG
was investigated. Therefore, even though neurodegen-
erative processes are suggested in D-AD, caution
should be taken to extrapolate the findings to other
brain areas. Third, although most demographic or
clinical features were relatively balanced between both
groups, the sample size was rather small. Thus, these
preliminary results need further replication with a lar-
ger sample size.
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Conclusions
We found decreased NAA/Cr and increased mI/Cr ratios
in the left ACG of AD patients with depression that corre-
lated with NPI and HAMD scores. This suggests that
neural and glial dysfunction in the left ACG is associated
with psychopathology of depression in AD patients. As
such, neurometabolic changes in the left ACG could be a
potential “biological signature” of depression related to
AD, and a target for novel treatments for AD patients with
depression.
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